Application of nanoscale polymer colloid carriers for targeted delivery of the brain-derived neurotrophic factor through the blood-brain barrier in experimental parkinsonism

Parkinson disease is one of the common age-related motor neurodegenerative diseases, in which dopamine neurons degeneration is considered to be pathognomic for the development of motor disfunction. Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family, which is considered t...

Full description

Bibliographic Details
Published in:Bulletin of Russian State Medical University
Main Author: Kapitonova M.Yu.; Alyautdin R.N.; Wan-Syazli R.W.A.L.; Nor-Ashikin M.N.K.; Ahmad A.; Norita S.; Dydykin S.S.
Format: Article
Language:English
Published: Pirogov Russian National Research Medical University 2018
Online Access:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85064264058&doi=10.24075%2fbrsmu.2018.072&partnerID=40&md5=eaa6ffb903e548f7ed4455e847a68d4a
id 2-s2.0-85064264058
spelling 2-s2.0-85064264058
Kapitonova M.Yu.; Alyautdin R.N.; Wan-Syazli R.W.A.L.; Nor-Ashikin M.N.K.; Ahmad A.; Norita S.; Dydykin S.S.
Application of nanoscale polymer colloid carriers for targeted delivery of the brain-derived neurotrophic factor through the blood-brain barrier in experimental parkinsonism
2018
Bulletin of Russian State Medical University
7
6
10.24075/brsmu.2018.072
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85064264058&doi=10.24075%2fbrsmu.2018.072&partnerID=40&md5=eaa6ffb903e548f7ed4455e847a68d4a
Parkinson disease is one of the common age-related motor neurodegenerative diseases, in which dopamine neurons degeneration is considered to be pathognomic for the development of motor disfunction. Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family, which is considered to be a key regulator of neuronal plasticity. BDNF, being a large molecule, does not pass through the blood-brain barrier (BBB). Synthetic polymer nanoparticles (NP), covered by surfactant, provide the phenomenon of “Trojan hoarse” and enable BDNF to penetrate into the brain tissue. For modelling of parkinsonism we used an intraperitoneal (i.p.) injection of neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) which was injected to the C57BL/6 mice with subsequest treatment with normal saline (group 1), BDNF (group 2), nanoparticulate BDNF (group 3) and surfactant-coated nanoparticulate BDNF (group 4). After 90 min, 24 hours, 72 hours and 7 days manifestations of parkinsonism were evaluated using behavioural tests of open field, rota-rod, assessment of the tremor, length of the body and pace. At the end of experiment the brain was sampled for histological evaluation of changes in the striatum and midbrain and concentration of BDNF in the brain tissues. The results of the experiments demonstrated that nanoparticulate BDNF covered with surfactant significanltly reduced rigidity of the skeletal muscles, oligokinesia and tremor, and also significantly increased BDNF concentration in the brain tissues. © 2018 Istituto Superiore di Sanita. All Rights Reserved.
Pirogov Russian National Research Medical University
25001094
English
Article
All Open Access; Gold Open Access; Green Open Access
author Kapitonova M.Yu.; Alyautdin R.N.; Wan-Syazli R.W.A.L.; Nor-Ashikin M.N.K.; Ahmad A.; Norita S.; Dydykin S.S.
spellingShingle Kapitonova M.Yu.; Alyautdin R.N.; Wan-Syazli R.W.A.L.; Nor-Ashikin M.N.K.; Ahmad A.; Norita S.; Dydykin S.S.
Application of nanoscale polymer colloid carriers for targeted delivery of the brain-derived neurotrophic factor through the blood-brain barrier in experimental parkinsonism
author_facet Kapitonova M.Yu.; Alyautdin R.N.; Wan-Syazli R.W.A.L.; Nor-Ashikin M.N.K.; Ahmad A.; Norita S.; Dydykin S.S.
author_sort Kapitonova M.Yu.; Alyautdin R.N.; Wan-Syazli R.W.A.L.; Nor-Ashikin M.N.K.; Ahmad A.; Norita S.; Dydykin S.S.
title Application of nanoscale polymer colloid carriers for targeted delivery of the brain-derived neurotrophic factor through the blood-brain barrier in experimental parkinsonism
title_short Application of nanoscale polymer colloid carriers for targeted delivery of the brain-derived neurotrophic factor through the blood-brain barrier in experimental parkinsonism
title_full Application of nanoscale polymer colloid carriers for targeted delivery of the brain-derived neurotrophic factor through the blood-brain barrier in experimental parkinsonism
title_fullStr Application of nanoscale polymer colloid carriers for targeted delivery of the brain-derived neurotrophic factor through the blood-brain barrier in experimental parkinsonism
title_full_unstemmed Application of nanoscale polymer colloid carriers for targeted delivery of the brain-derived neurotrophic factor through the blood-brain barrier in experimental parkinsonism
title_sort Application of nanoscale polymer colloid carriers for targeted delivery of the brain-derived neurotrophic factor through the blood-brain barrier in experimental parkinsonism
publishDate 2018
container_title Bulletin of Russian State Medical University
container_volume 7
container_issue 6
doi_str_mv 10.24075/brsmu.2018.072
url https://www.scopus.com/inward/record.uri?eid=2-s2.0-85064264058&doi=10.24075%2fbrsmu.2018.072&partnerID=40&md5=eaa6ffb903e548f7ed4455e847a68d4a
description Parkinson disease is one of the common age-related motor neurodegenerative diseases, in which dopamine neurons degeneration is considered to be pathognomic for the development of motor disfunction. Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family, which is considered to be a key regulator of neuronal plasticity. BDNF, being a large molecule, does not pass through the blood-brain barrier (BBB). Synthetic polymer nanoparticles (NP), covered by surfactant, provide the phenomenon of “Trojan hoarse” and enable BDNF to penetrate into the brain tissue. For modelling of parkinsonism we used an intraperitoneal (i.p.) injection of neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) which was injected to the C57BL/6 mice with subsequest treatment with normal saline (group 1), BDNF (group 2), nanoparticulate BDNF (group 3) and surfactant-coated nanoparticulate BDNF (group 4). After 90 min, 24 hours, 72 hours and 7 days manifestations of parkinsonism were evaluated using behavioural tests of open field, rota-rod, assessment of the tremor, length of the body and pace. At the end of experiment the brain was sampled for histological evaluation of changes in the striatum and midbrain and concentration of BDNF in the brain tissues. The results of the experiments demonstrated that nanoparticulate BDNF covered with surfactant significanltly reduced rigidity of the skeletal muscles, oligokinesia and tremor, and also significantly increased BDNF concentration in the brain tissues. © 2018 Istituto Superiore di Sanita. All Rights Reserved.
publisher Pirogov Russian National Research Medical University
issn 25001094
language English
format Article
accesstype All Open Access; Gold Open Access; Green Open Access
record_format scopus
collection Scopus
_version_ 1820775470029864960